Drug release follows the first-order pattern. In-vivo investigations reveal better anticancer activity of SoRE formulation compared to sorafenib standard preparation. Resealed erythrocytes loaded with sorafenib displayed first-order in-vitro release and promising anticancer activity in a rat model of hepatocellular carcinoma.